Efficacy, safety, and cost effectiveness of intravenous midazolam and flunitrazepam for primary insomnia in terminally ill patients with cancer: A retrospective multicenter audit study

Journal of Palliative Medicine

Volumn 10, Issue 5, 2007, Pages 1054-1062

  Matsuo, Naoki ^a   Morita, Tatsuya ^b  

^a SAITAMA CANCER CENTER   (Japan)

^b SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CHLORPROMAZINE; FLUNITRAZEPAM; HALOPERIDOL; HYDROXYZINE; MIDAZOLAM; SECOBARBITAL; TRAZODONE;

ADULT; AGED; APNEA; ARTICLE; BREATHING RATE; CANCER; CANCER PATIENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HANGOVER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PALLIATIVE THERAPY; RESPIRATION DEPRESSION; RESPIRATORY ARREST; SIDE EFFECT; TERMINAL DISEASE; TREATMENT DURATION;

AGED; ANTI-ANXIETY AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FLUNITRAZEPAM; HUMANS; JAPAN; MALE; MEDICAL AUDIT; MIDAZOLAM; NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TERMINALLY ILL;

EID: 35948992593     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2007.0016     Document Type: Article

References (34)

1. Mercadante S, Girelli D, Casuccio A: Sleep disorders in advanced cancer patients: Prevalence and factors associated. Support Care Cancer 2004;12:355-359.
2. Davidson JR, MacLean AW, Brundage MD, Schulze K: Sleep disturbance in cancer patients. Soc Sci Med 2002;54:1309-1321.
3. Savard J, Morin CM: Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol 2001;19:895-908.
4. Stiefel F, Ravavi D: Psychotropics in supportive care: First assess, then prescribe. Support Care Cancer 1999;7:371-372.
5. Goldberg RJ, Mor V: A survey of psychotropic use in terminal cancer patients. Psychosomatics 1985;26:745-751.
6. Matsuo N, Morita T: Intravenous infusion of midazolam and flunitrazepam for insomnia on Japanese palliative care units. J Pain Symptom Manage 2005;30:301-302.
7. Mercadante S, Ferrera P, Girelli D, Casuccio A: Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage 2005;30:354-358.
8. Morita T, Miyashita M, Shibagaki M, Hirai K, Ashiya T, Ishihara T, Matsubara T, Miyoshi I, Nakaho T, Nakashima N, Onishi H, Ozawa T, Suenaga K, Tajima T, Akechi T, Uchitomi Y: Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: A population-based survey in Japan. J Pain Symptom Manage 2006;31:306-316.
9. Chiu TY, Hu WY, Chuang RB, Cheng YR, Chen CY, Wakai S: Terminal cancer patients' wishes and influencing factors toward the provision of artificial nutrition and hydration in Taiwan. J Pain Symptom Manage 2004;27:206-214.
10. Smales EA, Sanders HG: Flunitrazepam in terminal care. Lancet 1989;26:501.
11. Smales OR, Smales EA, Sanders HG: Flunitrazepam in terminal care. J Paediatr Child Health 1993;29:68-69.
12. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, Sakonji M, Shima Y, Suenaga K, Takigawa C, Kohara H, Tani K, Kawamura Y, Matsubara T, Watanabe A, Yagi Y, Sasaki T, Higuchi A, Kimura H, Abo H, Ozawa T, Kizawa Y, Uchitomi Y; Japan Pain, Palliative Medicine, Rehabilitation, and Psycho-Oncology Study Group: Ethical validity of palliative sedation therapy: A multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 2005;30:308-319.
13. Amesbury BDW, Dunphy KP: The use of subcutaneous midazolam in the home care setting. Palliat Med 1989;3:299-301.
14. Bottomley DM, Hanks GW: Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990;5:259-261.
15. Burke AL, Diamond PL, Hulbert J, Yeatman J, Farr EA: Terminal restlessness-Its management and the role of midazolam. Med J Aust 1991;155:485-487.
16. Holdsworth MT, Adams VR, Chavez CM, Vaughan LJ, Duncan MH: Continuous midazolam infusion for the management of morphine-induced myoclonus. Ann Pharmacother 1995;29:25-29.
17. McNamara P, Minton M, Twycross RG: Use of midazolam in palliative care. Palliat Med 1991;5:244-249.
18. Ramani S, Karnad AB: Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. South Med J 1996;89:1101-1103.
19. Vermeeren A: Residual effects of hypnotics: Epidemiology and clinical implications. CNS Drugs 2004;18:297-328.
20. Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, Sakonji M, Shima Y, Suenaga K, Takigawa C, Kohara H, Tani K, Kawamura Y, Matsubara T, Watanabe A, Yagi Y, Sasaki T, Higuchi A, Kimura H, Abo H, Ozawa T, Kizawa Y, Uchitomi Y; Japan Pain, Palliative Medicine, Rehabilitation, and Psycho-Oncology Study Group: Efficcy and safety of palliative sedation therapy: A multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 2005;30:320-328.
21. Singer PA, Martin DK, Kelner M: Quality end of life care. Patients' perspectives. JAMA 1999;281:163-168.
22. Steinhauser KE, Clipp EC, Mc Neilly M, et al. In search of a good death: observations of patients, families, and providers. Ann Intern Med 2000;132:825-832.
23. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA: Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000;284:2476-2482.
24. Morita T, Tei Y, Inoue S: Correlation of the dose of midazolam for symptom control with administration periods: The possibility of tolerance. J Pain Symptom Manage 2003;25:369-375.
25. Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA, Schein RM, Spevetz A, Stone JR: Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: A executive summary. Crit Care Med 1995;23:1596-1600.
26. Shelly Mp, Sultan MA, Bodenham A, Park GR: Midazolam infusions in critically ill patients. Eur J Anaesth 1991;8:21-27.
27. Tobias JD: Tolerance, withdrawal, and physical dependency following long term sedation and analgesia of children in Pediatric ICU. Crit Care Med 2000;28:2122-2132.
28. Sjovall S, Kanto J, Kangas L, Pakkanen A: Comparison of midazolam and flunitrazepam for night sedation. Anaesth 1982;37:924-928.
29. Lingjaerde O, Bratlid T, Westby OC, Gordeladze JO: Effect of midazolam, flunitrazepam, and placebo against mid winter insomnia in northern Norway. Acta Psychiatr Scand 1983;67:118-129.
30. Dundee JW, Halliday NJ, Harper KW, Brogden RN: Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-543.
31. Soldatos CR, Kales A, Bixler EO: Behavioral side effects of benzodiazepine hypnotics. Clin Neuropharmacol 1985;8 Suppl 1:S112-7.
32. Ng K, von Gunten CF: Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. J Pain Symptom Manage 1998;16:307-316.
33. Hugel H, Ellershaw JE, Cook L, Skinner J, Irvine C: The prevalence, key causes and management of insomnia in palliative care patients. J Pain Symptom Manage 2004;27:316-321.
34. Stiefel F, Fainsinger R, Bruera E: Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 1992;7:94-98.